儿童间歇性哮喘与重度急性发作风险
该研究利用美国俄亥俄州医疗补助管理式医疗计划中2至18岁间歇性哮喘患者的行政索赔数据,识别出低风险亚组,并比较其第三年重度急性发作风险。结果显示,低风险亚组中每年使用0至2罐短效β2受体激动剂(SABA)的患者住院率0.08%、急诊就诊率0.97%、紧急护理就诊率0.55%,住院相对风险0.17(95%CI 0.06-0.52),重度急性发作相对风险0.18(95%CI 0.13-0.27);预防1例住院需治疗人数为5535,每年使用单支吸入性糖皮质激素预防1例住院的成本为779716美元。
要点
- 间歇性哮喘儿童中存在低风险亚组,其重度急性发作风险显著低于其他患者。
- 低风险亚组中每年使用0至2罐SABA者住院率仅0.08%,重度急性发作相对风险0.18。
- 对低风险亚组,当前GINA首步治疗推荐可能既不必要也不具成本效益。
核心结论
- 间歇性哮喘儿童中存在低风险亚组,其住院和重度急性发作风险较低,当前GINA首步治疗推荐对该亚组可能既不必要也不具成本效益。
研究设计与样本
- 基于美国俄亥俄州医疗补助管理式医疗计划行政索赔数据的队列研究,纳入2至18岁间歇性哮喘患者,要求连续3年参保,共13208例符合纳入标准。
主要发现
- 第三年,3935例低风险患者中,每年配发0至2罐SABA者哮喘住院3例(0.08%)、急诊就诊37例(0.97%)、紧急护理就诊21例(0.55%)。
- 与高风险患者相比,低风险患者住院相对风险为0.17(95%CI 0.06-0.52),重度哮喘急性发作相对风险为0.18(95%CI 0.13-0.27)。
- 低风险队列中,预防1例住院的需治疗人数为5535。
- 使用单支吸入性糖皮质激素每年预防1例住院的成本为779716美元。
临床怎么用
- 对间歇性哮喘儿童可评估其既往SABA使用等特征,识别重度急性发作低风险亚组。
- 对低风险亚组,可考虑个体化评估GINA首步治疗的必要性与成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Because of risk of severe asthma exacerbations, current Global Initiative for Asthma recommendations advise against use of short-acting beta-agonists (SABAs) alone as the first step in treating mild asthma. It is unclear if everyone with mild asthma carries equal risk for severe asthma exacerbations. RESEARCH QUESTION: Is there a subgroup of patients with mild asthma with very low risk of severe asthma exacerbations? STUDY DESIGN AND METHODS: This study cohort used administrative claims data for patients ages 2 to 18 years with intermittent asthma enrolled in Ohio Medicaid Managed Care Plans for 3 consecutive years. A low-risk group was identified for the first 2 years; in the third year, risk of severe asthma exacerbations was compared among the low-risk group and the rest of the cohort. RESULTS: A total of 13,208 patients met inclusion criteria. In the third year, among 3,935 low-risk patients, rates of asthma hospitalization, emergency department visits, and urgent care visits for those with 0 to 2 SABA canisters dispensed per year were 3 (0.08%), 37 (0.97%), and 21 (0.55%), respectively, with a relative risk of hospitalization of 0.17 (95% CI, 0.06-0.52) and a relative risk of severe asthma exacerbation of 0.18 (95% CI, 0.13-0.27) compared with high-risk patients. In the low-risk cohort, the number of patients needed to treat to prevent 1 hospitalization was 5,535. The cost to prevent 1 hospitalization using a single inhaler of inhaled corticosteroids per year was $779,716. INTERPRETATION: Our results show that among patients with mild asthma, there is a subgroup of low-risk patients with lower risk of hospitalization and severe asthma exacerbation in which current Global Initiative for Asthma recommendations for first-step treatment may neither be needed nor cost-effective.
引用
- Sheikh, Eisner, Wheaton, et al. Intermittent Asthma and Risk of Severe Exacerbation in Children. Chest. 2025. PMID: 40882701. doi:10.1016/j.chest.2025.07.4089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。